Trials / Completed
CompletedNCT02513550
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients With Moderate-to-Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,257 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
Detailed description
The purpose of this study is to evaluate both the safety and efficacy of ixekizumab dosing regimens. There are 3 study periods: Screening Period, Blinded Treatment Dosing Period, and Post-Treatment Follow-Up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixekizumab | Administered SQ |
| DRUG | Placebo | Administered SQ |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2016-11-01
- Completion
- 2017-08-03
- First posted
- 2015-07-31
- Last updated
- 2020-06-17
- Results posted
- 2018-04-18
Locations
125 sites across 14 countries: United States, Argentina, Australia, Canada, Czechia, Germany, Hungary, Japan, Mexico, Poland, Puerto Rico, Romania, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT02513550. Inclusion in this directory is not an endorsement.